Compare Organon & Co. Common Stock (OGN) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Waste Management, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Waste Management, Inc. trades at $218.93 (market cap $84.67B). The key difference: Waste Management, Inc. is far larger — about 23.5× Organon & Co. Common Stock's market cap, and Waste Management, Inc. pays the higher dividend (1.78%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Waste Management, Inc. for 131 Days on average.
| OGN | WM | |
|---|---|---|
Market Cap | $3.61B | $84.67B |
Volume | 1,808,049 | 1,534,456 |
Sector | Health | Industrials |
52-Week High | $13.81 | $246.51 |
52-Week Low | $5.70 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $11.03B | $107.47B |
Dividend Yield | 0.58% | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
WM trades at $215.75, up 2.18% today, with a bullish technical signal despite mixed momentum indicators. The company reported strong revenue growth to $25.20 billion in 2025 and beat earnings estimates in two of the last three quarters. Analyst consensus is positive with 54% buy ratings, and the stock offers a dividend yield supported by robust cash flow from operations of $6.04 billion.
Outlook remains favorable due to pricing power and acquisition strategy, but elevated debt levels and a high P/E ratio of 29.96 pose risks. Near-term performance hinges on Q3 2026 earnings results expected on October 27, 2026, with investor focus on margin sustainability and debt management amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
